Multidrug resistance in oncology and beyond: from imaging of drug efflux pumps to cellular drug targets.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Methods in molecular biology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/978-1-60761-416-6_2PMID 19949918
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy

  2008cited by this paper
• Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold Molecules

  2008cited by this paper
• Towards clinical VEGF imaging using the anti-VEGF antibody bevacizumab and Fab-fragment ranibizumab

  2008cited by this paper
• NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.

  2008cited by this paper
• Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.

  2008cited by this paper
• Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer

  2008cited by this paper
• Inhibition of heat shock protein 90 impairs epidermal growth factor–mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo

  2007cited by this paper
• RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.

  2007cited by this paper
• Determination and Prediction of P-Glycoprotein and Multidrug-Resistance-Related Protein Expression in Breast Cancer with Double-Phase Technetium-99m Sestamibi Scintimammography

  2007cited by this paper
• Multimodality imaging of the HER-kinase axis in cancer

  2007cited by this paper
• Hypoxia‐inducible factor‐1α contributes to hypoxia‐induced chemoresistance in gastric cancer

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• HER2 and response to paclitaxel in node-positive breast cancer.

  2007cited by this paper
• Immuno-PET: a navigator in monoclonal antibody development and applications.

  2007cited by this paper
• (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.

  2007cited by this paper
• In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft

  2007cited by this paper
• Targeting Heat Shock Protein 90 in Pancreatic Cancer Impairs Insulin-like Growth Factor-I Receptor Signaling, Disrupts an Interleukin-6/Signal-Transducer and Activator of Transcription 3/Hypoxia-Inducible Factor-1α Autocrine Loop, and Reduces Orthotopic Tumor Growth

  2007cited by this paper
• PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.

  2007cited by this paper
• Characterization of 89Zr-trastuzumab for clinical HER2 immunoPET imaging

  2007cited by this paper
• Heat shock protein 90: The cancer chaperone

  2007cited by this paper
• [18F]FBEM-ZHER2:342-Affibody molecule—a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography

  2007cited by this paper
• Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature

  2007cited by this paper
• Tumor imaging using a picomolar affinity HER2 binding affibody molecule.

  2006cited by this paper
• Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody

  2006cited by this paper
• Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET

  2006cited by this paper
• Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts

  2006cited by this paper
• Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

  2006cited by this paper
• Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.

  2006cited by this paper
• c-erbB2 Protein Overexpression in Breast Cancer as a Target for PET Using Iodine- 124-Labeled Monoclonal Antibodies

  2006cited by this paper
• Lessons from phase III clinical trials on anti-VEGF therapy for cancer

  2006cited by this paper
• Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

  2006cited by this paper
• Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments

  2005cited by this paper
• Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it.

  2005cited by this paper
• Engineered antibody fragments and the rise of single domains

  2005cited by this paper
• Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.

  2005cited by this paper
• Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma

  2005cited by this paper
• Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.

  2005cited by this paper
• Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

  2005cited by this paper
• Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET.

  2005cited by this paper
• Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments.

  2005cited by this paper
• Evolving role of positron emission tomography in breast cancer imaging.

  2005cited by this paper
• Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody.

  2005cited by this paper
• [177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells

  2005cited by this paper
• Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

  2004cited by this paper
• In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein

  2004cited by this paper
• Phosphatidylinositol 3′-Kinase Activation Leads to Multidrug Resistance Protein-1 Expression and Subsequent Chemoresistance in Advanced Prostate Cancer Cells

  2004cited by this paper
• Radiobromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br]undecahydro-bromo-7,8-dicarba-nido-undecaborate(1-) ion.

  2004cited by this paper
• Vascular endothelial growth factor: basic science and clinical progress.

  2004cited by this paper
• Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors.

  2004cited by this paper
• Correlation of expression of multidrug resistance protein and messenger RNA with 99mTc-methoxyisobutyl isonitrile (MIBI) imaging in patients with hepatocellular carcinoma.

  2004cited by this paper
• Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI).

  2004cited by this paper
• Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Preclinical characterisation of 111In‐DTPA‐trastuzumab

  2004cited by this paper
• A trial of single photon emission computed tomography of the liver with technetium-99m tetrofosmin to detect hepatocellular carcinoma.

  2003cited by this paper
• Technetium-99m Tetrofosmin SPECT Predicts Chemotherapy Response in Small Cell Lung Cancer

  2003cited by this paper
• A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin.

  2002cited by this paper
• The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography.

  2002cited by this paper
• Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.

  2002cited by this paper
• Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.

  2002cited by this paper
• Preliminary Study on Radioimmunodiagnosis of Experimental Tumor Models Using Technetium-99m-Labeled Anti-C-erbB-2 Monoclonal Antibody

  2002cited by this paper
• Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer (Stage IIIb or IV) with a Higher T Stage (> T2)

  2002cited by this paper
• Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis.

  2001cited by this paper
• Paclitaxel-Based chemotherapy for non-small cell lung cancer: predicting the response with 99mTc-tetrofosmin chest imaging.

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• In vivo measurement of [11C]verapamil kinetics in human tissues

  2001cited by this paper
• Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.

  2000cited by this paper
• A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.

  1999cited by this paper
• Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution.

  1999cited by this paper
• Visualization of multidrug resistance in vivo

  1999cited by this paper
• Early decrease of P-glycoprotein in the endothelium of the rat brain capillaries after moderate dose of irradiation.

  1999cited by this paper
• Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.

  1998cited by this paper
• Complete in vivo reversal of P‐glycoprotein pump function in the blood‐brain barrier visualized with positron emission tomography

  1998cited by this paper
• Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.

  1998cited by this paper
• Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.

  1997cited by this paper
• Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation.

  1995cited by this paper
• Noninvasive assessment of hepatobiliary and renal elimination of cysteinyl leukotrienes by positron emission tomography

  1995cited by this paper
• Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv.

  1993cited by this paper
• Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen.

  1993cited by this paper
• The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

  1993cited by this paper
• Radiolabeled antibody targeting of the HER-2/neu oncoprotein.

  1992cited by this paper
• c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies.

  1992cited by this paper
• What is the evidence that tumors are angiogenesis dependent?

  1990cited by this paper
• Translational Therapeutics

  year unknowncited by this paper

• A microfluidic device enabling drug resistance analysis of leukemia cells via coupled dielectrophoretic detection and impedimetric counting

  2021cites this paper
• Effect of EGR1-Mediated LncRNA HOTAIR on MRP1 Gene Expression and MDR in Lung Cancer

  2020cites this paper
• Indole Curcumin Reverses Multidrug Resistance by Reducing the Expression of ABCB1 and COX2 in Induced Multidrug Resistant Human Lung Cancer Cells

  2020cites this paper
• An anti-cancer binary system activated by bacteriophage HK022 Integrase

  2017cites this paper
• Physiologic and Molecular Basis of PET in Cancer Imaging

  2017cites this paper
• Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response.

  2016cites this paper
• Radiopharmaceuticals for the Imaging of ABC-Transporter-Mediated Multidrug Resistance in Cancer

  2015cites this paper
• Bench to bedside molecular functional imaging in translational cancer medicine: to image or to imagine?

  2015cites this paper
• Blood–brain barrier and drug delivery

  2015cites this paper
• Imaging physiological ABC transporter expression and its relation to disease using Tc-99m-hexakis-methoxy-isobutyl isonitrile (Tc-99m-MIBI)

  2015influential citation
• Chemoresistance, Cancer Stem Cells, and miRNA Influences: The Case for Neuroblastoma

  2015cites this paper
• Innovative in vitro method and permeability estimation procedure to predict drug transport across the blood-brain barrier

  2014cites this paper
• Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.

  2014cites this paper
• Multidrug Resistance Protein

  2014cites this paper
• Imaging of multidrug resistance in cancer

  2011influential citation
• ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions.

  2011cites this paper
• Functionalization of nanocarriers for efficient combination drug delivery

  2011cites this paper
• Drug penetration across the blood-brain barrier: an overview.

  2010cites this paper
• Chinese a Nti鄄 Cancer a Ssociation

  year unknowncites this paper